During the past decade, Chiara Maria Grana conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chiara Maria Grana" #1 collaborator was "Agenzia Italiana del Farmaco" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Chiara Maria Grana" are "Neuroendocrine Tumors" (1 trials) and "Pancreatic Neuroendocrine Tumor" (1 trials). Many other conditions were trialed in "Chiara Maria Grana" in a lesser frequency.

Most popular intervention types in "Chiara Maria Grana" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Y90-DOTA-Tyr3-Octreotide" (1 trials) and "peptide receptor radionuclide therapy with Y-90-DOTATOC" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chiara Maria Grana" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Chiara Maria Grana". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Chiara Maria Grana, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Chiara Maria Grana, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".